FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNeumora Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NMRA
Neumora Therapeutics, Inc. Common Stock Stock AnalysisComprehensive stock analysis for Neumora Therapeutics, Inc. Common Stock (NMRA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNMRA
NMRA
Neumora Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NMRA
  1. Home
  2. Stocks
  3. Neumora Therapeutics, Inc. Common Stock
NT

Neumora Therapeutics, Inc. Common Stock

🇺🇸NMRA•NASDAQ
NT

Neumora Therapeutics, Inc. Common Stock

🇺🇸NMRA•NASDAQ
Market cap
$69.43M
Sentiment

Your view on NMRA

Mkt Cap
$69.43M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Neumora Therapeutics, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Daljit Singh Aurora
Headquarters
490 Arsenal Way, Watertown, DE, US
Industry
Biotechnology
Sector
Healthcare
CEO
Daljit Singh Aurora
Headquarters
490 Arsenal Way, Watertown, DE, US
Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.

The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.

In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease.

The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Neumora Therapeutics, Inc. Common Stock from FRC's valuation model, read against the market price. NMRA last traded at $0.37; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Neumora Therapeutics, Inc. Common Stock. Starting points for Neumora Therapeutics, Inc. Common Stock: EPS -$1.03, beta 3.14 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Neumora Therapeutics, Inc. Common Stock. Neumora Therapeutics, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Neumora Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Neumora Therapeutics, Inc. Common Stock stands at -$1.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$5.67

average of 3 firms, last 12 months

 

$5.67

Low $4.00

Median $5.00

High $8.00

 

Analyst Ratings

Buy7 firms, last 12 months
  • Strong Buy0
  • Buy6
  • Hold1
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.17-$0.13-$0.89-$0.57
Low estimate-$0.19-$0.14-$0.96-$0.73
High estimate-$0.14-$0.12-$0.69-$0.32
No. of analysts4256
Year-ago EPS-$0.35-$0.30-$1.45—
Growth+50.7%+56.0%+38.4%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$16000.00$16000.00$625000.00$2.90M
Low estimate$16000.00$16000.00$625000.00$2.90M
High estimate$16000.00$16000.00$625000.00$2.90M
No. of analysts1185
Year-ago revenue$0.00$0.00$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Jul 13, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Neumora Therapeutics, Inc. Common Stock. Neumora Therapeutics, Inc. Common Stock has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NMRA20 companies · 8 funds
Compare NMRA with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ADCTADC Therapeutics S.A.Biotechnology$160M
  • ALMSAlumis Inc. Common StockBiotechnology$665M
  • AUTLAutolus Therapeutics plcBiotechnology$303M
  • BCYCBicycle Therapeutics plcBiotechnology$223M
  • FDMT4D Molecular Therapeutics, Inc.Biotechnology$624M
  • FULCFulcrum Therapeutics, Inc.Biotechnology$283M
  • LXRXLexicon Pharmaceuticals, Inc.Biotechnology$779M
  • OMEROmeros CorporationBiotechnology$1.2B

More Biotechnology companies

  • MIRMMirum Pharmaceuticals, Inc.NASDAQ$6.0B
  • MISTMilestone Pharmaceuticals Inc.NASDAQ$45M
  • MLECMoolec Science S.A.NASDAQ$617,200
  • MLECWMoolec Science S.A.NASDAQ$76,243
  • MLLCFMolecular Partners AGOTC$131M
  • MLTXMoonLake ImmunotherapeuticsNASDAQ$998M
  • MLYSMineralys Therapeutics, Inc.NASDAQ$1.3B
  • MMIRFMedMira Inc.OTC$9M
  • MNKDMannKind CorporationNASDAQ$1.3B
  • MNOVMediciNova, Inc.NASDAQ$69M
  • MNPRMonopar Therapeutics Inc.NASDAQ$488M
  • MOLNMolecular Partners AGNASDAQ$103M

ETFs holding Neumora Therapeutics, Inc. Common Stock

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • IWMiShares Russell 2000 ETF$76.6B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • IWOiShares Russell 2000 Growth ETF$13.7B in assets0.00%
  • VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
  • PRFZInvesco RAFI US 1500 Small-Mid ETF$2.6B in assets0.00%
  • SMMDiShares Russell 2500 ETF$4.1B in assets0.00%
  • VHTVanguard Health Care ETF$19.1B in assets0.00%

Largest holders first, then the funds most concentrated in NMRA.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Neumora Therapeutics, Inc. Common Stock, and how their positions are changing. At a $69.4M market value, institutional positions materially move Neumora Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Neumora Therapeutics, Inc. Common Stock executives and directors. Shares of Neumora Therapeutics, Inc. Common Stock have traded between $0.61 and $11.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Neumora Therapeutics, Inc. Common Stock. Coverage tracks Neumora Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Neumora Therapeutics, Inc. Common Stock.

NMRA Analysis
Fair
Past1
Growth2
Health5
Profit1
Value1

News

Latest Market News